retatrutide fda approval status 2025 HAS NOT BEEN APPROVED YET & CURRENTLY IN PHASE III CLINICAL TRIALS⛔️ Retatrutide is not currently FDA-approved, as it is in Phase III clinical trials with anticipated completion in 2025–2026 and Retatrutide, an experimental weight-loss drug,
Description
At worst, this is weaponized incompetence of the worst kind and naked profiteering which exploits a highly vulnerable group of people
GLP-1 medications may contribute to this by slowing down digestion
Important context: the FDA has warned that retatrutide is not a component of an FDA-approved drug and has not been found safe/effective for any condition
Weekly Dulaglutide versus daily Liraglutide in metformin-treated uncontrolled T2D patients is compared for safety and efficacy
Dosing protocols and clinical evidence
